Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02796261 : Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
PhasePhase 3
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be eligible for participation
in this study:

- Surgical or biopsy-proven diagnosis of WHO grade 3 AA.

- Unequivocal evidence of first AA tumor progression or recurrence = 3 months prior to
randomization based on MRI criteria for tumor progression using enlarging Gd-contrast
enhancement and/or T2 hyperintensity. Patients with non-measurable Gd contrast
enhancing tumors will only be eligible if there is no necrosis seen on MRI and/or
histopathological confirmation of AA per standard of care procedures is obtained.

- First tumor progression or recurrence following surgical resection or biopsy, if
resection is not feasible, EBRT and temozolomide chemotherapy.

- Completion of EBRT = 6 months prior to randomization.

- A patient whose AA tumor has progressed or recurred and has had another surgical
resection prior to randomization will be eligible if a) pathology review confirms AA,
and b) post-surgical MRI demonstrates measurable tumor on T2/FLAIR.

- Karnofsky Performance Status (KPS) score of = 70.

Exclusion Criteria:

Patients who meet any of the following exclusion criteria are not eligible for study
participation:

- MRI defining progression is consistent with a diagnosis of glioblastoma or radiation
necrosis.

- Patients who are considered to be refractory to EBRT and temozolomide but who have not
progressed.

- Prior systemic therapy for recurrence of AA.

- Presence of extracranial or leptomeningeal disease.

- Prior lomustine use.

- Any other clinical condition or prior therapy that, in the opinion of the
Investigator, would make the patient unsuitable for the study.

- Pregnant or breastfeeding.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02796261      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740